Last Updated on November 11, 2024 by The Health Master
The Gland Pharma received a zero-observation certificate on Form 483 from the United States Food and Drug Administration (USFDA) for its Visakhapatnam facility.
The USFDA conducted the good manufacturing practice (GMP) inspection at the company’s VSEZ Sterile Oncology facility at Visakhapatnam between July 20 and July 28.
The inspection concluded with zero observations on Form 483 and a classification of No Action Indicated (NAI).
On July 14, the company received one observation after the USFDA conducted a GMP inspection at Dundigal facility at Hyderabad during July 3-14.
The regulator had last month issued one observation on the company’s Pashamylaram facility at Hyderabad after GMP and pre-approval inspection (PAI) for seven products.
Understanding GMP, cGMP, and WHO-GMP
USFDA Warning Letter resolved: Lupin, Goa, Pithampur
USFDA concludes inspection at Eugia Pharma with zero observation
USFDA issues Form 483 with 3 observations to Aurobindo: Hyderabad
USFDA issues Form 483 with 8 observations to Biocon: Malaysia
USFDA issues Form 483 with one observation to Gland Pharma: Hyderabad
Physical and Chemical parameters of Excipient affect its functionality and Drug Quality: Experts
Illegal Drugs worth more than Rs. 50 Lakh seized from warehouses in Agra
USFDA gives nod to market this cancer treatment generic injection
Drug recall: Sun Pharma, Alembic recall these drugs due to this reason
Indian Medical Device Industry urges Govt to Recall Import Order for Pre-Owned Medical Devices
Latest on Indian Pharmacopoeia Commission (IPC)
European Medicines Agency issues EU GMP certification to Indoco: Baddi
Lok Sabha passes The Jan Vishwas Bill to Amend Drugs and Cosmetics Act
NPPA fixed ceiling prices of 915 scheduled formulations till mid July
